Peptide Stack for Fat Loss: GLP-1 + GH-Axis + MOTS-C (2026)

Three peptides, three different fat-loss levers — and the one behavior base that decides whether any of it spares your muscle.

Abstract: A well-built peptide stack for fat loss layers three independent mechanisms — appetite and insulin control (GLP-1 / triple-agonist), growth-hormone-driven visceral-fat loss and muscle sparing (tesamorelin + ipamorelin), and mitochondrial fat oxidation (MOTS-C). This guide explains how the layers synergise, grades the evidence behind each honestly, and lays out the research-reported doses, timing, cautions and monitoring labs that separate a smart protocol from a dangerous one.

Why build a peptide stack for fat loss?

The single most common mistake in metabolic protocols is treating “fat loss” as one problem. It isn’t. Body recomposition is rate-limited at several places at once: how much you eat, how sensitive you are to insulin, how much growth hormone you pulse at night, how well your mitochondria burn fat for fuel, and whether you hold onto muscle while the scale drops. A peptide stack for fat loss works because each compound hits a different bottleneck — so their effects add up instead of overlapping.

That is also why the wrong stack backfires. Pile three appetite suppressants together and you get nausea, not synergy. The logic below comes straight from our stack architecture for fat loss and the clinical framing physicians like Dr. Craig Koniver describe — combine compounds whose mechanisms are complementary, keep each at the lowest effective dose, and let a behavior base do the heavy lifting.

A quick honesty note up front, because it governs everything that follows: most of the muscle-sparing and mitochondrial claims here rest on animal data or clinical observation, not large human fat-loss trials. The GLP-1 layer is the only part with phase-2/3 human weight-loss evidence. We flag the grade of every claim so you can weigh it yourself. This is research and educational information, not medical advice.

The three layers, and what each one actually does

Layer 1 — GLP-1 / triple-agonist: appetite and insulin (strongest evidence)

This is the foundation, and the only layer with hard human outcome data. Incretin agonists lower the brain’s body-weight “set point,” blunt appetite, and improve insulin sensitivity.

• Tirzepatide (GLP-1 + GIP) drove a mean ~20.9% body-weight reduction at 72 weeks in the SURMOUNT-1 trial (Jastreboff 2022). [clinical]
• Retatrutide (GLP-1 + GIP + glucagon) pushed a mean ~24.2% reduction at 48 weeks at the 12 mg dose in its phase-2 trial — and the curve had not yet plateaued (Jastreboff 2023). The added glucagon arm directly raises energy expenditure and hepatic fat oxidation, which is why it edges the dual agonists. [clinical]

The catch is well documented: a meaningful share of GLP-1 weight loss is lean mass unless you defend it. That single fact is the reason the other two layers — and the behavior base — exist. For the head-to-head, see retatrutide vs tirzepatide and the full retatrutide review.

Layer 2 — GH-axis (tesamorelin + ipamorelin): visceral fat + muscle sparing

Growth hormone does two things a GLP-1 can’t: it preferentially mobilises visceral fat and it helps protect lean tissue during a deficit. Rather than inject GH directly (which overrides physiology and shuts down feedback), the stack augments the natural nighttime pulse with a GHRH analog plus a selective secretagogue.

• Tesamorelin is a GHRH analog, FDA-approved for visceral adiposity, with 1,000+ patient data: roughly +80% IGF-1 and −11–18% visceral fat, plus lower triglycerides and inflammation (Falutz 2007; Stanley 2014). [clinical]
• Ipamorelin is the cleanest GH secretagogue — GH potency comparable to GHRP-6 but highly selective, so no meaningful cortisol or prolactin spike (Raun 1998; Sigalos 2018). [clinical/animal] Used with a GHRH it produces a documented ~66% synergistic GH increase; used alone it desensitises and fails. [educational]

This is exactly the “fat-loss combination” Koniver describes compounding into a single bedtime shot. [anecdote/protocol] For the standalone picture, see tesamorelin for visceral fat, ipamorelin for beginners, and tesamorelin vs ipamorelin.

Layer 3 — MOTS-C: mitochondrial fat oxidation (weakest human evidence)

MOTS-C is a 16-amino-acid mitochondrial-derived peptide nicknamed “exercise in a vial.” It activates AMPK → SIRT1 / PGC-1α, shifting cells toward fat oxidation and improving glucose uptake — the metabolic-flexibility layer that matters most when a GLP-1 has dragged your energy and training output down.

Be clear-eyed about the evidence: in obese mice MOTS-C produced ~20% body-weight and ~25% blood-sugar reductions (Lee 2015) [animal], and the only human signal is a phase-1 trial of its analog CB4211 (NAFLD: −25% liver enzymes, −6% fasting glucose) [clinical-analog]. There is no human trial of exogenous MOTS-C itself, and it is FDA category-2 (not compoundable) and WADA-banned. Treat it as the experimental layer, not a staple.

The behavior base (this is what makes the stack work)

No peptide overrides the fundamentals — they amplify them. Across every credible source, the same non-negotiables appear:

• Resistance training + ~1 g protein per pound of bodyweight. This is the single intervention that converts GLP-1 weight loss from “fat and muscle” into “mostly fat.”
• A modest deficit and ≤2 lb/week loss rate — fast loss strips muscle and rebounds.
• 7–9 hours of sleep, which is also when the GH-axis layer does its work.
• Aerobic / Zone-2 work, ideally timed near the MOTS-C dose for synergy.

If these aren’t in place, add the behavior base before adding a third or fourth peptide.

A research-framed protocol

The table below summarises what has been used or reported in the research and clinical-anecdote literature — it is a map for understanding the studies, not a prescription. Doses are illustrative starting points reported by physicians and trials; individual protocols must be built with a licensed clinician.

Layer	Compound	Reported starting range	Timing	Cycling	Evidence grade
1. Appetite/insulin	Retatrutide or Tirzepatide	Micro-dose; titrate slowly, loss ≤2 lb/wk	Weekly	Continuous, slow titration	Clinical (phase 2/3)
2a. Visceral fat	Tesamorelin	~1 mg → max ~2 mg	Pre-sleep, no food ~2–4 h prior	5 on / 2 off; ~3–4 mo on / 1 mo off	Clinical
2b. GH secretagogue	Ipamorelin	~100 mcg ceiling	With the GHRH, pre-sleep, no carbs ~45 min prior	Same as tesamorelin	Clinical/animal
3. Mitochondrial	MOTS-C	~5 mg, 3×/week	30 min pre-aerobic exercise / AM	4 weeks on / 4 off	Animal + analog phase-1

Tesamorelin and ipamorelin are frequently compounded into a single nighttime injection (the ipamorelin + tesamorelin blend exists for this reason); the GLP-1 stays a separate weekly shot, and MOTS-C — where legal and clinician-supervised — is dosed around training.

Sequencing logic

A common phased approach: start the GLP-1 alone and titrate until appetite and weight are moving and tolerated; add the GH-axis pair once a deficit is established and resistance training is consistent (it counters the muscle loss); consider MOTS-C last, when fuel flexibility or GLP-1-related fatigue becomes the limiter. Adding everything at once makes side effects impossible to attribute.

The two failure modes (read this before stacking)

Most of the real risk in a fat-loss stack concentrates in two places:

1. Muscle loss. GLP-1s cause it without resistance training and protein; rapid loss makes it worse. The GH-axis layer and the behavior base are the countermeasures — not optional extras.
2. Insulin resistance. This is the under-appreciated one. GH secretagogues reduce insulin sensitivity, and tesamorelin can raise fasting glucose and A1C early — neutralised by ~6 months only if visceral fat is actually lost. In the trial population, those who lost <8% visceral fat saw +8 mg/dL fasting glucose and +0.2 A1C at one year, and ~5% developed diabetes vs 1% on placebo (Stanley 2014; GH-selection synthesis). The lesson: the GH layer earns its place only in someone lean enough to lose the visceral fat it targets. MOTS-C adds a separate concern — folate-cycle modulation can raise homocysteine.

For the compound-by-compound rundown, see the peptide side-effects and safety guide.

Monitoring and labs

Because the failure modes are metabolic, the monitoring is too. A reasonable baseline-and-follow-up panel reported in this context:

• Fasting glucose, fasting insulin, HbA1c — the insulin-resistance early-warning system; check before starting the GH layer and at ~6–12 weeks.
• IGF-1 — to confirm the GH-axis is working without overshooting youth-range.
• Lean mass (DEXA or consistent method) and weight-loss rate (target ≤2 lb/week).
• Homocysteine and folate if running MOTS-C; use methylated B-vitamins on off days only.
• Lipids and liver enzymes as general metabolic markers.

Forms, sourcing and COA

All of these are injectable subcutaneous peptides (oral MOTS-C is effectively zero bioavailability). The sourcing rule is the same one that runs through every credible discussion: gray-market “research use only / not for human consumption” vials can carry LPS endotoxin, which is cumulatively inflammatory and a real anaphylaxis risk. Work through a licensed physician and a compounding pharmacy, and insist on a third-party Certificate of Analysis for identity, purity and endotoxin. Note that several of these compounds (BPC-157, CJC-1295, MK-677 historically) have moved on and off the FDA compounding lists — verify current status before assuming availability.

FAQ

What is the best peptide stack for fat loss? There isn’t a universal “best” — the right stack matches your bottleneck. If appetite and weight are the problem, the GLP-1 layer alone does most of the work. If you’re already lean-ish and chasing stubborn visceral fat while keeping muscle, the GH-axis layer adds the most. MOTS-C is for fuel flexibility and training output. The strongest evidence sits with the GLP-1 layer.

Can I run retatrutide and tesamorelin together? They target different mechanisms (appetite/insulin vs GH-driven visceral-fat loss), so they’re mechanistically complementary, and clinicians do combine them. The caution is metabolic: both can stress insulin sensitivity, so glucose/A1C monitoring matters, and resistance training plus protein are required to keep the loss from including muscle.

Will a peptide stack make me lose muscle? A GLP-1 will, unless you resistance-train and eat adequate protein and keep loss to ≤2 lb/week. The GH-axis layer helps spare lean tissue. The behavior base is what actually protects muscle — peptides only assist.

Where does MOTS-C fit? As the experimental, last-added layer for mitochondrial fat oxidation and energy — useful when a GLP-1 has tanked your training. Its human evidence is limited to an analog (CB4211); it’s WADA-banned and FDA category-2, so it’s the least staple of the three.

How long until results? GLP-1 effects on appetite begin within weeks; meaningful weight loss accrues over months (phase-2 retatrutide was still dropping at 48 weeks). Tesamorelin’s visceral-fat effect builds over ~3–6 months. None of this is a fast process done safely.

References

1. Jastreboff AM, et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine 389:514-526. doi:10.1056/NEJMoa2301972
2. Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine 387:205-216. doi:10.1056/NEJMoa2206038
3. Falutz J, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine 357:2359-2370. doi:10.1056/NEJMoa072375
4. Stanley TL, et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA 312:380-389. doi:10.1001/jama.2014.6334
5. Lee C, et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism 21:443-454. doi:10.1016/j.cmet.2015.02.009
6. Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology 139:552-561. doi:10.1530/eje.0.1390552
7. Sigalos JT, Pastuszak AW (2018). The Safety and Efficacy of Growth Hormone Secretagogues. Sexual Medicine Reviews 6:45-53. doi:10.1016/j.sxmr.2017.12.004

---

Research and educational use only. This article describes what has been reported in published research and clinical observation; it is not medical advice and not a recommendation to use any compound. Several peptides discussed are investigational and/or restricted (e.g., MOTS-C is FDA category-2 and WADA-banned). Do not start, combine, or dose any peptide except under the supervision of a qualified, licensed clinician.